Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Hormonal–alkylating conjugate
Estramustine
Emcyt · ESTR
An estradiol-mustard conjugate whose renal signal is hemodynamic — estrogenic fluid retention and thromboembolism, not direct nephrotoxicity.
MildHormonal-alkylating conjugate · approved 1981
Metastatic or progressive (hormone-refractory) prostate carcinoma
Signature kidney injury
Prerenal / Hemodynamic AKI
Renal injury is hemodynamic/prerenal rather than a quantified direct rate. The dominant safety liability is venous (and arterial/cardiovascular) thromboembolism with fluid retention/edema; in randomized data the majority of cardiovascular complications occurred within the first year.
Source: Petrylak et al., NEJM 2004
Mechanism of kidney injury
Largely functional/prerenal via estrogenic activity: sodium and fluid retention with edema, and a markedly increased risk of venous thromboembolism (and arterial/cardiovascular events) from estrogen-mediated procoagulant changes. Fluid shifts, heart failure and thrombotic events can produce prerenal/cardiorenal azotemia; there is no characteristic direct tubulotoxic lesion.
Clinical presentation
Lower-extremity edema, weight gain and dyspnea (fluid overload/heart failure), DVT/PE, and a prerenal rise in creatinine. Cardiovascular/thromboembolic events often occur within the first 1-2 months. Gynecomastia and GI toxicity are common estrogenic/mustard effects.
Onset
Edema/VTE within weeks to the first 2 months.
Reversibility
Reversible
Anticancer mechanism
Conjugate of estradiol and a nitrogen mustard (normustine) joined by a carbamate link. It acts mainly as an antimicrotubule agent — binding microtubule-associated proteins and beta-tubulin to disrupt the mitotic spindle (rather than primarily as an alkylator) — while the estradiol moiety suppresses gonadotropins and testosterone; it synergizes with taxanes.
Management
Diuretics for fluid retention, anticoagulation for venous thromboembolism, and holding the drug for significant cardiovascular/thrombotic events while managing the cardiorenal physiology.
Risk factors
- Prior cardiovascular disease or thromboembolism
- Heart failure and edematous states
- Longer/higher estramustine exposure (toxicity reduced by shortened dosing schedules)
Prevention
- Cardiovascular risk assessment before starting
- Consider prophylactic anticoagulation in some regimens (e.g. low-dose warfarin in docetaxel-estramustine protocols)
- Sodium/fluid monitoring and shortened estramustine exposure schedules
Note · Established (1981) agent; renal injury is prerenal/hemodynamic (fluid retention plus VTE), not direct tubular toxicity, and is not separately quantified.
Clinical depth
Renal dose adjustment
No established CrCl-based dose algorithm; use caution with cardiovascular/cerebrovascular disease and in heart failure. It is contraindicated with active thromboembolic disorders.
Dialyzability & ESKD dosing
Not characterized/not relevant (highly protein-bound and lipophilic).
Differential diagnosis
Estrogenic fluid retention/heart failure versus VTE-related cardiorenal injury versus prerenal volume depletion (GI losses) versus progressive prostate disease/obstruction.
Monitoring
- Weight, edema and blood pressure
- Signs of DVT/PE
- LFTs, calcium and glucose
- Periodic cardiovascular assessment
Key trials & series
- SWOG 9916 (Petrylak, NEJM 2004) — pivotal docetaxel/estramustine survival trial documenting excess cardiovascular events
- Randomized estramustine vs conventional estrogen (Hedlund, Scand J Urol Nephrol Suppl 1980) — cardiovascular complication timing
Clinical pearls
- The renal signal is hemodynamic/prerenal from estrogenic fluid retention and thromboembolism — not direct nephrotoxicity.
- VTE and cardiovascular events are the dominant safety liability and drove estramustine's decline in favor of taxanes.
- One-day oral estramustine dosing reduces thromboembolic and GI toxicity.
- Adding estramustine to docetaxel improved survival (SWOG 9916) but at the cost of more cardiovascular/embolic events versus mitoxantrone.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKI
Beyond the kidney
Class-level context for the major non-renal toxicities of hormonal–alkylating conjugates.
Ophthalmic
Keratopathy, uveitis, retinopathy
- Visual disturbance (crizotinib)
Hepatic / Liver
Transaminitis, hepatitis, VOD/SOS
- Transaminitis
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- CNS effects (lorlatinib)
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.Petrylak DP et al. · N Engl J Med 2004 · PMID 15470214SWOG 9916 phase 3 — pivotal estramustine survival trial documenting excess cardiovascular events.PMIDCardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients.Hedlund PO et al. · Scand J Urol Nephrol Suppl 1980 · PMID 6938012Randomized data on estramustine cardiovascular/thromboembolic complication timing.PMIDPhase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma.Sinibaldi VJ et al. · Cancer 2002 · PMID 11920502Shortened estramustine schedule reduces thromboembolic/edema toxicity.PMIDDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.Tannock IF et al. · N Engl J Med 2004 · PMID 15470213TAX 327 — companion phase 3 contextualizing estramustine-free docetaxel and the mitoxantrone comparator.PMIDThe tumor lysis syndrome.Howard SC et al. · N Engl J Med 2011 · PMID 21561350General onconephrology reference for metabolic AKI mechanisms relevant to prostate-cancer therapy.PMIDLow-Dose Estramustine Phosphate and Concomitant Low-Dose Acetylsalicylic Acid in Heavily Pretreated Patients With Advanced Castration-Resistant Prostate Cancer.Petrioli R et al. · Clin Genitourin Cancer 2015 · PMID 25920994Phase 2 of low-dose estramustine with aspirin thromboprophylaxis — no venous thromboembolism observed, supporting the thrombosis-mitigation strategy.
Related agents
Other agents sharing the same signature kidney injury.